Ra Capital Management, L.P. - Insider Trading & Ownership

Entity
Company
Location
200 Berkeley Street, 18 Th Floor, Boston, MA
Summary
The estimated value of insider holdings of Ra Capital Management, L.P. is at least $2.04B dollars as of December 10, 2024. Ra Capital Management, L.P. is the Director, 10%+ Owner of Janux Therapeutics, Inc. and owns shares of Janux Therapeutics, Inc. (JANX) stock worth about $482M. Ra Capital Management, L.P. is the Director, 10%+ Owner of Aerovate Therapeutics, Inc. and owns shares of Aerovate Therapeutics, Inc. (AVTE) stock worth about $198M. Ra Capital Management, L.P. is the Director, 10%+ Owner of Tyra Biosciences, Inc. and owns shares of Tyra Biosciences, Inc. (TYRA) stock worth about $154M. Ra Capital Management, L.P. is the Former 10% Owner of iTeos Therapeutics, Inc. and owns shares of iTeos Therapeutics, Inc. (ITOS) stock worth about $137M. Ra Capital Management, L.P. is the Director, 10%+ Owner of Nkarta, Inc. and owns shares of Nkarta, Inc. (NKTX) stock worth about $131M. Ra Capital Management, L.P. is the Director, 10%+ Owner of Cytek Biosciences, Inc. and owns shares of Cytek Biosciences, Inc. (CTKB) stock worth about $127M. Ra Capital Management, L.P. is the Director, 10%+ Owner of 89bio, Inc. and owns shares of 89bio, Inc. (ETNB) stock worth about $111M. Ra Capital Management, L.P. is the Director, 10%+ Owner of PepGen Inc. and owns shares of PepGen Inc. (PEPG) stock worth about $97.7M. Ra Capital Management, L.P. is the Director, 10%+ Owner of ARS Pharmaceuticals, Inc. and owns shares of ARS Pharmaceuticals, Inc. (SPRY) stock worth about $97.5M. Ra Capital Management, L.P. is the 10%+ Owner of Fulcrum Therapeutics, Inc. and owns shares of Fulcrum Therapeutics, Inc. (FULC) stock worth about $79.4M. Ra Capital Management, L.P. is the 10%+ Owner of 4D Molecular Therapeutics, Inc. and owns shares of 4D Molecular Therapeutics, Inc. (FDMT) stock worth about $74.5M. Ra Capital Management, L.P. is the Director, 10%+ Owner of Acrivon Therapeutics, Inc. and owns shares of Acrivon Therapeutics, Inc. (ACRV) stock worth about $67.3M. Ra Capital Management, L.P. is the Director of Mineralys Therapeutics, Inc. and owns shares of Mineralys Therapeutics, Inc. (MLYS) stock worth about $47.7M. Ra Capital Management, L.P. is the 10%+ Owner of Kala Pharmaceuticals, Inc. and owns shares of KALA BIO, Inc. (KALA) stock worth about $47.4M. Ra Capital Management, L.P. is the Director, 10%+ Owner of Acumen Pharmaceuticals, Inc. and owns shares of Acumen Pharmaceuticals, Inc. (ABOS) stock worth about $45.3M. Ra Capital Management, L.P. is the Director of Cidara Therapeutics, Inc. and owns shares of Cidara Therapeutics, Inc. (CDTX) stock worth about $35.5M. Ra Capital Management, L.P. is the Former 10% owner of Enliven Therapeutics, Inc. and owns shares of Enliven Therapeutics, Inc. (ELVN) stock worth about $32.1M. Ra Capital Management, L.P. is the Director, 10%+ Owner of Solid Biosciences Inc. and owns shares of Solid Biosciences Inc. (SLDB) stock worth about $23.2M. Ra Capital Management, L.P. is the Director of Therapeutics Acquisition Corp. and owns shares of POINT Biopharma Global Inc. stock worth about $13.7M. Ra Capital Management, L.P. is the Director, 10%+ Owner of LENZ Therapeutics, Inc. and owns shares of LENZ Therapeutics, Inc. (LENZ) stock worth about $13.5M. Ra Capital Management, L.P. is the Director, 10%+ Owner of Eliem Therapeutics, Inc. and owns shares of Climb Bio, Inc. (CLYM) stock worth about $11M. Ra Capital Management, L.P. is the 10%+ Owner of RxSight, Inc. and owns shares of RxSight, Inc. (RXST) stock worth about $10.3M. Ra Capital Management, L.P. is the Director of Black Diamond Therapeutics, Inc. and owns shares of Black Diamond Therapeutics, Inc. (BDTX) stock worth about $8.77M. Ra Capital Management, L.P. is the 10%+ Owner of AN2 Therapeutics, Inc. and owns shares of AN2 Therapeutics, Inc. (ANTX) stock worth about $325K. Ra Capital Management, L.P. is the Director, 10%+ Owner of Wave Life Sciences Ltd. and owns shares of Wave Life Sciences Ltd. (WVE) stock worth about $40K.
All Insider Reports
All Insider Reports

Ownership of Ra Capital Management, L.P.

Symbol Company Relationship Holdings Value Past Year Net Change Change % Report Period
JANX Janux Therapeutics, Inc. Director, 10%+ Owner $482M +$119M +32.7% Oct 18, 2024
AVTE Aerovate Therapeutics, Inc. Director, 10%+ Owner $198M Jun 17, 2024
TYRA Tyra Biosciences, Inc. Director, 10%+ Owner $154M +$19.8M +14.7% Nov 8, 2024
ITOS iTeos Therapeutics, Inc. Former 10% Owner $137M +$100M +270% May 10, 2024
NKTX Nkarta, Inc. Director, 10%+ Owner $131M +$60M +85.1% Jun 13, 2024
CTKB Cytek Biosciences, Inc. Director, 10%+ Owner $127M Mar 14, 2022
ETNB 89bio, Inc. Director, 10%+ Owner $111M +$48.3M +77.8% Nov 14, 2024
PEPG PepGen Inc. Director, 10%+ Owner $97.7M +$27.2M +38.6% Jun 20, 2024
SPRY ARS Pharmaceuticals, Inc. Director, 10%+ Owner $97.5M +$13.3M +15.8% Jun 20, 2024
FULC Fulcrum Therapeutics, Inc. 10%+ Owner $79.4M Sep 12, 2024
FDMT 4D Molecular Therapeutics, Inc. 10%+ Owner $74.5M Dec 9, 2024
ACRV Acrivon Therapeutics, Inc. Director, 10%+ Owner $67.3M Jun 20, 2024
MLYS Mineralys Therapeutics, Inc. Director $47.7M May 22, 2024
KALA KALA BIO, Inc. 10%+ Owner $47.4M May 26, 2022
ABOS Acumen Pharmaceuticals, Inc. Director, 10%+ Owner $45.3M Jun 10, 2024
CDTX Cidara Therapeutics, Inc. Director $35.5M Nov 26, 2024
ELVN Enliven Therapeutics, Inc. Former 10% owner $32.1M Feb 23, 2023
SLDB Solid Biosciences Inc. Director, 10%+ Owner $23.2M +$5M +27.5% Jan 11, 2024
PNT POINT Biopharma Global Inc. Director $13.7M Jun 29, 2021
LENZ LENZ Therapeutics, Inc. Director, 10%+ Owner $13.5M Mar 21, 2024
CLYM Climb Bio, Inc. Director, 10%+ Owner $11M +$50M Jun 27, 2024
RXST RxSight, Inc. 10%+ Owner $10.3M Aug 3, 2021
BDTX Black Diamond Therapeutics, Inc. Director $8.77M Jul 5, 2023
ANTX AN2 Therapeutics, Inc. 10%+ Owner $325K -$3.81M -92.1% Aug 9, 2024
WVE Wave Life Sciences Ltd. Director, 10%+ Owner $40K Aug 12, 2024
ICVX Icosavax, Inc. Director, 10%+ Owner $0 Feb 19, 2024
ARTV Artiva Biotherapeutics, Inc. Director, 10%+ Owner Jul 22, 2024
BCAX Bicara Therapeutics Inc. Director, 10%+ Owner Sep 16, 2024
BOLD Boundless Bio, Inc. 10%+ Owner Apr 2, 2024
DICE DICE Therapeutics, Inc. Former 10% owners and Director Aug 9, 2023
FMTX Forma Therapeutics Holdings, Inc. Director, 10%+ Owner Oct 14, 2022
STSA Satsuma Pharmaceuticals, Inc. Former 10% Owner Jun 8, 2023
SEPN Septerna, Inc. Director, 10%+ Owner Oct 28, 2024
VOR Vor Biopharma Inc. Director, 10%+ Owner May 23, 2024
HOWL Werewolf Therapeutics, Inc. Director, 10%+ Owner May 24, 2024

Insider Transactions Reported by Ra Capital Management, L.P.:

Sym Company Class Transaction % Value $ * Price $ Shares Shares After Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.